STOCK TITAN
  1. Home
  2. News
  3. NBTX

Nanobiotix - NBTX STOCK NEWS

Welcome to our dedicated news page for Nanobiotix (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nanobiotix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nanobiotix's position in the market.

News
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Rhea-AI Summary
NANOBIOTIX provided a business update and reported full-year 2023 financial results. The company entered into a global agreement with Janssen for its radioenhancer NBTXR3, saw positive clinical trial results in head and neck cancer and pancreatic cancer, and expects multiple clinical readouts in 2024. The company reported €75.3 million in cash and cash equivalents as of December 31, 2023, with a cash runway into Q3 2025. The 2023 Universal Registration Document was filed with the French financial market authority and the 2023 Annual Report on Form 20-F was filed with the U.S. Securities and Exchange Commission. Nanobiotix also announced a conference call and webcast scheduled for April 25, 2024, to discuss these updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
earnings
-
News
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
Rhea-AI Summary
NANOBIOTIX will announce its fourth-quarter and full-year 2023 operational and financial update on April 24, 2024, followed by a conference call and webcast on April 25, 2024. The Company, a late-clinical stage biotechnology firm focusing on physics-based approaches for cancer treatment, will review year-end results and business activities for 2023 during the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
News
Voting Rights and Shares Capital of the Company
Rhea-AI Summary
Nanobiotix releases updated total number of voting rights and shares outstanding, following French Commercial Code regulations. The company's shares are traded on Euronext Paris and Nasdaq under the ticker symbol NBTX.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
none
News
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Rhea-AI Summary
Nanobiotix completes Phase 1 study for NBTXR3 in inoperable, recurrent NSCLC patients, confirming injection feasibility and safety profile, paving the way for Phase 2 development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
clinical trial
-
News
Nanobiotix to Present at Upcoming Investor Conferences in March
Rhea-AI Summary
Nanobiotix, a biotechnology company, will participate in fireside chats at the Guggenheim Healthy Altitudes Summit and Leerink Partners Global Biopharma Conference. Laurent Levy and Bart Van Rhijn will present at the events, providing insights into the company's progress and future plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
-
News
Voting Rights and Shares Capital of the Company
Rhea-AI Summary
Nanobiotix announces the total number of voting rights and shares outstanding as of January 31, 2024, in compliance with French regulations. The company has 47,133,328 shares outstanding and 48,850,400 total voting rights, with 48,828,282 exercisable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
News
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
Rhea-AI Summary
Nanobiotix, a late-clinical stage biotechnology company, announced that its co-founder and chairman, Laurent Levy, and CFO, Bart Van Rhijn, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024. The chat will be webcast live and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
-
News
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
Rhea-AI Summary
Nanobiotix, a biotechnology company, achieved operational requirements in the ongoing Phase 3 study for NBTXR3, resulting in a $20M milestone payment from Janssen. The collaboration aims to bring potential benefits of NBTXR3 to patients with head and neck cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
clinical trial
-
News
Voting Rights and Shares Capital of the Company
Rhea-AI Summary
Nanobiotix (NBTX) announces the monthly publication of the total number of voting rights and shares comprising its capital, in accordance with the French Commercial Code and the General Regulation of the French Financial Markets Authority. As of December 31, 2023, Nanobiotix had 47,133,328 shares outstanding, with a total of 48,849,317 voting rights, of which 48,827,199 were exercisable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
News
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
Rhea-AI Summary
Nanobiotix (NANO - NBTX) Announces Global Development and Commercialization Agreement for NBTXR3 with Janssen
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
Stock NBTX logo
Nanobiotix

Nasdaq:NBTX

NBTX Rankings

#3521 Ranked by Market Cap
#264 Ranked by Stock Gains
N/A Ranked by Dividends

NBTX Stock Data

287.38M
20.76M
19.68%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
France
Paris

About NBTX

nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea